Literature DB >> 7979302

Clinical trial of fusidic acid for lepromatous leprosy.

S G Franzblau1, G P Chan, B G Garcia-Ignacio, V E Chavez, J B Livelo, C L Jimenez, M L Parrilla, R F Calvo, D L Williams, T P Gillis.   

Abstract

Fusidic acid was assessed for antileprosy activity in nine lepromatous leprosy patients. Patients received fusidic acid at either 500 mg/day for 12 weeks or 750 mg/day for 4 weeks followed by 500 mg/day for 8 weeks. All patients showed time-dependent clinical improvement and decreases in bacillary morphological index, radiorespirometric activity and PCR signal, and in serum phenolic glycolipid I. Fusidic acid appears to be a weakly bactericidal antileprosy agent which may have a role in the multidrug treatment of leprosy pending an evaluation of lepra-reaction-suppressive activity.

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 7979302      PMCID： PMC284609          DOI： 10.1128/AAC.38.7.1651

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  20 in total

1.  Double-blind evaluation of BACTEC and Buddemeyer-type radiorespirometric assays for in vitro screening of antileprosy agents.

Authors:  S G Franzblau; A N Biswas; P Jenner; M J Colston
Journal:  Lepr Rev       Date:  1992-06       Impact factor: 0.537

2.  A clinical trial of minocycline in lepromatous leprosy.

Authors:  R H Gelber; K Fukuda; S Byrd; L P Murray; P Siu; M Tsang; T H Rea
Journal:  BMJ       Date:  1992-01-11

3.  Fusidic acid is highly active against extracellular and intracellular Mycobacterium leprae.

Authors:  S G Franzblau; A N Biswas; E B Harris
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

4.  Clinical trial of pefloxacin and ofloxacin in the treatment of lepromatous leprosy.

Authors:  J H Grosset; B H Ji; C C Guelpa-Lauras; E G Perani; L N N'Deli
Journal:  Int J Lepr Other Mycobact Dis       Date:  1990-06

Review 5.  Structure-activity relationships in fusidic acid-type antibiotics.

Authors:  W von Daehne; W O Godtfredsen; P R Rasmussen
Journal:  Adv Appl Microbiol       Date:  1979       Impact factor: 5.086

6.  Comparative in-vitro activities of ten fluoroquinolones and fusidic acid against Mycobacterium spp.

Authors:  D Van Caekenberghe
Journal:  J Antimicrob Chemother       Date:  1990-09       Impact factor: 5.790

7.  Fusidic acid, an immunosuppressive drug with functions similar to cyclosporin A.

Authors:  K Bendtzen; M Diamant; V Faber
Journal:  Cytokine       Date:  1990-11       Impact factor: 3.861

8.  Clinical trial of clarithromycin for lepromatous leprosy.

Authors:  G P Chan; B Y Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  Detection of Mycobacterium leprae and the potential for monitoring antileprosy drug therapy directly from skin biopsies by PCR.

Authors:  D L Williams; T P Gillis; P Fiallo; C K Job; R H Gelber; C Hill; S Izumi
Journal:  Mol Cell Probes       Date:  1992-10       Impact factor: 2.365

10.  Clinical trial of sparfloxacin for lepromatous leprosy.

Authors:  G P Chan; B Y Garcia-Ignacio; V E Chavez; J B Livelo; C L Jimenez; M L Parrilla; S G Franzblau
Journal:  Antimicrob Agents Chemother       Date:  1994-01       Impact factor: 5.191
View more
  1 in total

1.  Bactericidal activity of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients.

Authors:  B Ji; S Sow; E Perani; C Lienhardt; V Diderot; J Grosset
Journal:  Antimicrob Agents Chemother       Date:  1998-05       Impact factor: 5.191
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.